EGFR and non-small cell lung carcinoma: Dacomitinib (Reed and Smaill, 2016) (trade name: Vizimpro), an anilinoquinazoline derivative, recently received FDA approval (Shirley, 2018; Roskoski, 2019) as a tyrosine kinase inhibitor (TKI) for the treatment of locally advanced or metastatic NSCLC, as it irreversibly inhibits three out of four HER families: HER-1, HER-2, and HER-4 tyrosine kinases (Gonzales et al., 2008).